33012453
2020 Nov
The evolution of locoregional therapies in the last decade has been refined with improved patient selection and a development of a more personalized approach. In doing so, there has been associated improved outcomes and less toxicity. With the rapidly changing landscape of systemic therapy, the role of locoregional therapies alone or in combination for downstaging and curative intent will continue to evolve.
HCC; Liver cancer; Locoregional therapy; Systemic therapy; TACE; TARE; Y90.
